Two complementary MIT papers reported design and screening of novel ionizable lipids and degradable LNP formulations that delivered influenza mRNA vaccines in mice at roughly 1/100th the dose required by current industry LNPs. In Nature Nanotechnology and associated reports, researchers described cyclic amino alcohol ionizable lipids (AMG1541) and degradable chemistries that enhanced endosomal escape and immunogenicity in preclinical models. The teams argue reduced dose requirement could lower manufacturing cost per vaccine and may mitigate dose‑related side effects. These are preclinical murine results; translational and toxicology work will be needed before human studies. (Clarification: LNP = lipid nanoparticle, the carrier system for mRNA delivery.)